Abstract

Invasive breast cancers with HER2 gene amplification are associated with poor outcome. Heterogeneous HER2 amplification has been observed in up to 41% of breast cancers, depending upon its definition. Carcinogenesis is driven by intra-tumour heterogeneity. Molecular diversity enables cancer cells to circumvent specific targeted treatment. In this study, we compared the genetic differences between admixed HER2-positive and HER2-negative breast cancer components. This in-depth analysis investigated the heterogeneity in their somatic mutational landscape.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.